bpc-157 clinical trials humans BPC-157: What the Science Says (Zero Human Trials) bpc 157 human clinical trial

Individuals with a history of proliferative disorders or those currently undergoing treatments that influence cell signaling pathways must consult an oncologist or endocrinologist before use

This helps optimize absorption and avoids over-saturation Switch Nostrils : Use the other nostril for the next dose

Mood and anxiety disorders precede development of functional gastrointestinal disorders in patients but not in the population

Some endogenous neuropeptides do cross via saturable transport systems, and there is speculation that DSIP may do so, but this has not been rigorously demonstrated for exogenously administered peripheral DSIP in humans